Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress.

Astex Pharmaceuticals Announces First Data Showing Early Combination Treatment of Resistance in Preclinical Models

Astex Pharmaceuticals Announces First Data Showing Early Combination Treatment of HSP90 Inhibitor AT13387 With Targeted Agents Delays Emergence of Resistance in Preclinical Models

Astex Pharmaceuticals Announces IND Candidate: ASTX727 a Potential Best-in-Class Oral Hypomethylator

Astex Pharmaceuticals Announces IND Candidate: ASTX727 a Potential Best-in-Class Oral Hypomethylator

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Data at the Upcoming European Cancer Congress (ECCO-ESMO-ESTRO)

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Data at the Upcoming European Cancer Congress (ECCO-ESMO-ESTRO)

Astex Pharmaceuticals Announces Presentation of Updated Results of SGI-110-01 Study inPatients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology Association

Astex Pharmaceuticals Announces Presentation of Updated Results of SGI-110-01 Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology Association